United States· US:0990-7905_357fc68c-2f4c-4f4c-9e26-a66ff54c59ff
Potassium Chloride in Dextrose
A sulfonamides and potassium in combination product containing dextrose monohydrate and potassium chloride injection, solution, registered in United States by ICU Medical Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- dextrose monohydrate and potassium chloride injection, solution
- Manufacturer
- ICU Medical Inc.
- Country
- United States (US)
- ATC code
- C03CB
- ATC class
- Sulfonamides and potassium in combination
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 3, 2026
Packs & prices · 1
- ndc11099079050912 POUCH in 1 CASE (0990-7905-09) / 1 BAG in 1 POUCH / 1000 mL in 1 BAG
Regulatory notes
Same class
Other records under C03CB
Sulfonamides and potassium in combination, as other registers publish it.
- United StatesColgate Sensitive Complete ProtectionColgate-Palmolive Company
- United StatesColgate Sensitive Enamel HealthColgate-Palmolive Company
- United StatesIonosol MB and DextroseICU Medical Inc.
- United StatesLactated RingersICU Medical Inc.
- United StatesLactated RingersICU Medical Inc.
- United StatesLactated Ringers and DextroseICU Medical Inc.
- United StatesLymph CareHealth and Harmony Products
- United StatesNORMOSOL-M AND DEXTROSEICU Medical Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bb596140-0c2b-48c4-968d-4669be351b18 GET /v1/drugs/bb596140-0c2b-48c4-968d-4669be351b18?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "LX22YL083G",
"rxcui": "1299920",
"inchikey": "SPFMQWBKVUQXJV-BTVCFUMJSA-N",
"display_name": "DEXTROSE MONOHYDRATE",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "INTRAVENOUS",
"spl_meta": {
"ff67f638-5b53-406a-962a-87773a91fc48": {
"match": "brand_token",
"title": "POTASSIUM CITRATE TABLET, EXTENDED RELEASE [BRYANT RANCH PREPACK]",
"spl_version": "104",
"published_date": "2026-05-28"
}
},
"productid": "0990-7905_357fc68c-2f4c-4f4c-9e26-a66ff54c59ff",
"productndc": "0990-7905",
"dosage_form": "INJECTION, SOLUTION",
"orange_book": {
"appl_no": "018371",
"products": [
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "5GM/100ML;149MG/100ML",
"product_no": "001",
"approval_date": "Approved Prior to Jan 1, 1982"
},
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "5GM/100ML;298MG/100ML",
"product_no": "002",
"approval_date": "Approved Prior to Jan 1, 1982"
},
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "5GM/100ML;224MG/100ML",
"product_no": "003",
"approval_date": "Approved Prior to Jan 1, 1982"
}
],
"appl_type": "N"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "DEXTROSE MONOHYDRATE; POTASSIUM CHLORIDE",
"shortage_reason": "Dextrose Monohydrate 5% Injection",
"shortage_status": "current",
"proprietary_name": "Potassium Chloride in Dextrose",
"active_ingred_unit": "g/100mL; g/100mL",
"application_number": "NDA018371",
"marketing_category": "NDA",
"nonproprietary_name": "dextrose monohydrate and potassium chloride injection, solution",
"start_marketing_date": "20201120",
"active_numerator_strength": "5; .149"
}See everything about dextrose monohydrate and potassium chloride injection, solution.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.